ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

IARC Director Denies NCI Staff Interference With Monograph

May 28, 1982

ACCC Presentations On Care In Community

March 27, 1981

Chemoprevention Concept Approved By DCPC Bard Uses Biological Markers To Assess Risk Modulation

September 27, 1985

House committee Seeks $239 Million Cut In Clinton’s NIH Budget

March 11, 1994

DCCP Board Approves Concepts Of $2.6 Million In New Competing Projects, $1.2 Million In Recompetitions

September 25, 1981

In Brief: Ford Decides Against Asking For Recision Of NCI Funds After Congress Overrides Verto

October 8, 1976